November 23, 2025
I.Financial Updates 1.UBS Upgrades Novartis to Neutral:Analysts highlight strong management confidence in core therapeutic areas and key mid-term drug candidates.(ID:20923077) 2.Barclays Downgrades Novartis to Underweight:Move follows […]